ImmunityBio (IBRX) Convertible Debt (2022 - 2026)

ImmunityBio (IBRX) has 5 years of Convertible Debt data on file, last reported at $678.4 million in Q1 2026.

• Convertible Debt for Q1 2026 came in at $678.4 million, up 39.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $678.4 million (up 39.67% YoY), and the FY2025 annual result was $477.1 million, up 3.29% from the prior year.
• Convertible Debt grew to $678.4 million in Q1 2026 per IBRX's latest filing, from $477.1 million in the prior quarter.
• Over five years, Convertible Debt peaked at $678.4 million in Q1 2026 and troughed at $165.3 million in Q3 2023.
• A 5-year average of $467.9 million and a median of $492.1 million in 2025 frame the typical range for Convertible Debt.
• On a YoY basis, Convertible Debt climbed as much as 255.73% in 2024 and fell as far as 19.95% in 2024.
• A 5-year view of Convertible Debt shows it stood at $241.3 million in 2022, then soared by 139.13% to $577.0 million in 2023, then slipped by 19.95% to $461.9 million in 2024, then advanced by 3.29% to $477.1 million in 2025, then jumped by 42.19% to $678.4 million in 2026.
• Business Quant data shows IBRX's Convertible Debt at $678.4 million in Q1 2026, $477.1 million in Q4 2025, and $500.8 million in Q3 2025.